• BIGBEAR Pharmaceutical объявляет об одобрении биниметиниба[Binimetinib] и энкорафениба[Encorafenib] в Лаосе

    Вьентьян, Лаос - 12 октября 2024 г. - BigBear Pharma, ведущая биофармацевтическая компания, занимающаяся разработкой и коммерциализацией инновационных методов лечения рака, сегодня объявила, что Биниметиниб [Binimetinib] и Энкорафениб [Encorafenib] были одобрены Министерством здравоохранения Лаоса. Одобренные препараты: Биниметиниб [Binimetinib] продается под торговой маркой MEKTODX, регистрационный номер в Лаосе: 09L1096/24 Энкорафениб [Encorafenib]…

  • BIGBEAR Pharmaceutical announces the approval of Binimetinib and Encorafenib in Laos

    Vientiane, Laos - October 12 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Binimetinib and Encorafenib have been approved by the Ministry of Health of Laos. Approved drugs are: Binimetinib sold under the brand name MEKTODX, Laos registration number: 09L1096/24 Encorafenib…

  • BIGBEAR Pharmaceutical announces the approval of Letermovir in Laos

    Vientiane, Laos - September 20, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that 2 products have been approved by the Ministry of Health of Laos. Approved drugs are: Letermovir: sold under the brand name LETEDX.Letermovir is an antiviral drug…

  • BIGBEAR Pharmaceutical announces the approval of Adagrasib in Laos

    Vientiane, Laos - July 14, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Adagrasibm have been approved by the Ministry of Health of Laos. Approved drugs are: Adagrasib: sold under the brand name ADADX. Adagrasib, a KRAS G12C inhibitor, irreversibly and selectively binds KRAS G12C,…

  • BIGBEAR Pharmaceutical announces the approval of Larotrectinib in Laos

    Vientiane, Laos - May 30, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Larotrectinib have been approved by the Ministry of Health of Laos. Approved drugs are: Larotrectinib sold under the brand name LARODX.  Larotrectinib is an inhibitor of tropomyosin kinase…

  • ハイイータン® Gumarontinib (MET inhibitor) has been successfully approved in Japan

    June 24, 2024, Haihe Biopharma Co., Ltd. (referred as “Haihe”) announced that Ministry of Health, Labor and Welfare of Japan (厚生労働省) approved New Drug Application (“NDA”) of Gumarontinib (SCC244) for the treatment of unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping mutation. The indication…

  • BIGBEAR Pharmaceutical объявляет об одобрении препарата Selumetinib в Лаосе

    Вьентьян, Лаос – 8 апреля 2024 г. – BigBear Pharma, ведущая биофармацевтическая компания, занимающаяся разработкой и коммерциализацией инновационных методов лечения рака, сегодня объявила, что два продукта были одобрены Министерством здравоохранения Лаоса. Разрешенные препараты: Селуметиниб (Selumetinib): продается под торговой маркой SEMEDX. Селуметиниб (Selumetinib) был одобрен для продажи в США 10 апреля…

  • BIGBEAR Pharmaceutical announces the approval of Selumetinib in Laos

    Vientiane, Laos - April 8, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that 2 products have been approved by the Ministry of Health of Laos. Approved drugs are: Selumetinib: sold under the brand name SEMEDX. Selumetinib was approved for…

  • Unlocking Global Health Opportunities: Mitotane (MITODX)

    Introduction  If you are looking for new business opportunities in the pharmaceutical industry, there is a product for you: Generic Mitotane sold under the brand name MITODX. BIGBEAR Pharmaceutical: A Beacon of Innovation in Laos  BigBear Pharmaceutical is one of the regular chemical pharmaceutical companies in Laos. Accompanied by investors and the…

  • How many generic versions of Epclusa (Sofosbuvir/Velpatasvird) are there?

    Original Brand drug Epclusa (Sofosbuvir/Velpatasvir) is the world’s first all-oral, pan-genotypic, single-tablet hepatitis C treatment regimen, taken orally once daily, for all 6 genotypes (GT-1, -2, -3, -4, -5,-6) Treatment of hepatitis C patients. Currently, there are 26 versions of sofosbuvir/velpatasvir tablets available in the Asia-Pacific region. Generic Drugs Sofosbuvir-velpatasvir Other…


Top